Some good news today:
Compared to earlier Delta infections, after controlling for factors associated with severe disease, SGTF-infected individuals had a lower odds of severe disease (aOR 0.3, 95% CI 0.2-0.6). Conclusion Early analyses suggest a reduced risk of hospitalisation among SGTF-infected individuals when compared to non-SGTF infected individuals in the same time period, and a reduced risk of severe disease when compared to earlier Delta-infected individuals. Some of this reducton is likely a result of high population immunity
1) Omicron is less serious (70% fewer severe outcomes) but not enough to prevent another wave of unvax deaths.
Vaccinated MS patients on anti-CD20 treatment show robust T-cell responses that recognize S from the circulating Delta and Omicron variants. Response rates increased after the third dose, demonstrating that a booster dose might improve cytotoxic T-cell mediated protection against severe disease in patients with low humoral response.
2) T cell response is robust, even in immunocompromised people to the vaccine, after a booster. Vaccination is the path out of the pandemic.
https://www.medrxiv.org/content/10.1101/2021.12.21.21268116v1
https://www.medrxiv.org/content/10.1101/2021.12.20.21268128v1